Conformational characterization of a novel anti-HER2 candidate antibody.

Conformational characterization of a novel anti-HER2 candidate antibody.

Regulatory agencies establish that a broad physicochemical and biological characterization is necessary for the evaluation of comparability between a biosimilar candidate product and a reference commercial drug. Between them, conformational characterization of proteins is of vital importance to dete...

Full description

Bibliographic Details
Main Authors:	Leina Moro Pérez, Azalia de la Caridad Rodríguez Taño, Lázaro Roberto Martín Márquez, Jose Alberto Gómez Pérez, Aisel Valle Garay, Rancés Blanco Santana
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0215442

Similar Items

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
by: Alberto Ocaña, et al.
Published: (2020-01-01)

Production and Characterization of Anti-Her2 Monoclonal Antibodies
by: A.S. Tabatabaei-Panah, et al.
Published: (2008-01-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Recapitulation of the anti-Idiotype antibodies as vaccine candidate
by: Ahsan Naveed, et al.
Published: (2018-03-01)

HER1 Vaccine: An autologous EGFR vaccine candidate to treat epithelial tumors
by: Belinda Sánchez, et al.

Presence of anti-Leishmania antibodies in candidates for kidney transplantation
by: Adriana de Oliveira França, et al.
Published: (2020-09-01)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
by: Jackie Cheng, et al.
Published: (2020-09-01)

Solution conformation of engineered antibodies
by: Lu, Yanling
Published: (2007)

Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
by: Aliya K. Stanova, et al.
Published: (2020-05-01)

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody
by: Mohammad Mehdi Amiri, et al.
Published: (2019-03-01)

Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
by: Hongmei Xiao, et al.
Published: (2019-09-01)

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
by: Florian Kast, et al.
Published: (2021-06-01)

Peptidomimetic-based antibody surrogate for HER2
by: Mengmeng Zheng, et al.
Published: (2021-09-01)

Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
by: Marianne Nordlund Broughton, et al.
Published: (2017-06-01)

Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer
by: Bender, Brendan
Published: (2016)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
by: Shengnan Yu, et al.
Published: (2017-11-01)

Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
by: Bechard Theresa, et al.
Published: (2010-05-01)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
by: Shengnan Yu, et al.
Published: (2019-08-01)

Dissecting antibodies with regards to linear and conformational epitopes.
by: Björn Forsström, et al.
Published: (2015-01-01)

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
by: Alejandro Vazquez-Martin, et al.
Published: (2009-01-01)

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
by: Ceran Ceyhan, et al.
Published: (2012-10-01)

A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
by: Xiaoqiong Wu, et al.
Published: (2018-04-01)

Carvacrol: An in silico approach of a candidate drug on HER2, PI3Kα, mTOR, HER-α, PR, and EGFR receptors in the breast cancer
by: Herrera-Calderon, Oscar, et al.
Published: (2021)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
by: Andres Lopez-Albaitero, et al.
Published: (2017-03-01)

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
by: Yassamine Lazrek, et al.
Published: (2013-03-01)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)

The generation of domainspeccific monoclonal anti-CD4 antibodies as novel candidate HIV therapies
by: Jugnarain, Vinesh Mervyn
Published: (2016)

Role of BamHI-A Rightward Frame 1 in Epstein–Barr Virus-Associated Epithelial Malignancies
by: Rancés Blanco, et al.
Published: (2020-12-01)

Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
by: Marta Westwood, et al.
Published: (2015-07-01)

Aβ Conformation Dependent Antibodies and Alzheimer's Disease
by: Sehlin, Dag
Published: (2010)

Isolation of monoclonal antibodies with predetermined conformational epitope specificity.
by: Anton M Sholukh, et al.
Published: (2012-01-01)

Capturing transient antibody conformations with DNA origami epitopes
by: Ping Zhang, et al.
Published: (2020-06-01)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
by: Michael Simon, et al.
Published: (2021-06-01)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
by: I-Chun Chen, et al.
Published: (2021-10-01)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
by: Mehdi Mohammadi, et al.
Published: (2021-02-01)

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
by: Mattan Levi, et al.
Published: (2020-12-01)

Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody
by: Hu Yi, et al.
Published: (2012-07-01)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
by: Aura Muntasell, et al.
Published: (2017-11-01)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
by: Oscar Herrera-Calderon, et al.
Published: (2020-01-01)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01)